Driving breakthrough discoveries for better healthcare outcomes.
Explore SPARC’s work in action, including panel discussions, articles, and more.
The COVID-19 pandemic disrupted every part of biomedical research. This article explores how philanthropy can help rebuild the research ecosystem by funding recovery efforts, supporting vulnerable scientists, and strengthening institutions.
Therapeutic development relies on collaboration to bring new treatments to patients. The Nonprofits: A Growing Force in Drug Development report explores how nonprofits are accelerating this process and shaping innovative models.
SPARC partnered with the Shanahan Family Foundation to conduct a landscape assessment of Alzheimer’s Disease research and funding patterns, culminating in the development of a Giving Smarter Guide.
SPARC conducted a landscape analysis of the GBM research and funding ecosystem to highlight opportunities where philanthropy can accelerate progress and translate promising science into life-extending treatments.
The New Vision of Health guide explores how longer lives, advances in technology, and innovative approaches to care are reshaping aging—emphasizing prevention, connectedness, and breakthrough dementia research.
SPARC and the Depression and Bipolar Support Alliance surveyed over 6,000 people, revealing treatment gaps, overlooked youth, and the need to center lived experience in bipolar disorder research.
SPARC’s Giving Smarter Guide highlights how philanthropy can accelerate the adoption of precision health by funding tools, data sharing, and infrastructure to make proactive care a reality.
This report examines a decade of global funding for tau-related neurodegenerative disease research, offering insight into progress, gaps, and opportunities for future discovery.
Mental health is an integral part of health and well-being. However, mental health conditions are highly prevalent and largely under-treated.
SPARC and the Rainwater Charitable Foundation have partnered to advance tauopathy research, highlighting how philanthropy can drive collaboration and accelerate new diagnostics and treatments.
Pfizer’s decision to end new drug research for Alzheimer’s and Parkinson’s underscores the urgent need for coordinated investment and innovation to address the growing crisis of neurodegenerative disease.
Lipedema is a painful condition with limited treatment options. This guide highlights the state of research and opportunities for philanthropy to help improve care.